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 Abstract  1 
The experiments described here were designed to characterize the status of 2 
susceptibility/resistance to albendazole (ABZ) and triclabendazole (TCBZ) of a 3 
Fasciola hepatica isolate (named CEDIVE isolate) recovered from infected sheep 4 
from in Gualeguay (Argentina) and maintained under laboratory conditions. Two 5 
separate clinical efficacy experiments were performed. Experiment 1: Sheep 6 
artificially infected with the CEDIVE isolate were randomly distributed into an 7 
untreated control and an ABZ (7.5 mg/kg) treated groups (n= 4 each). The systemic 8 
exposure of ABZ metabolites was assessed in those ABZ-treated infected animals. 9 
Additionally, an untreated control group and a TCBZ (10 mg/kg) treated group was 10 
included in Experiment 2 (n=4 each). The fluckicidal efficacy of ABZ and TCBZ was 11 
assessed by comparison of the number of flukes recovered from untreated and treated 12 
sheep at 15 days post-treatment. The efficacy against the CEDIVE isolate of F. 13 
hepatica was 29% (ABZ) and 100 % (TCBZ). The plasma drug exposure (expressed 14 
as AUC and Cmax) observed in the ABZ treated animals (Experiment 1), was in 15 
agreement with data obtained in previous studies, which indicate that the low ABZ 16 
efficacy was not related to the quality of the pharmaceutical product and/or to a low 17 
systemic availability of the active drug/metabolite. The results reported here, clearly 18 
show that the CEDIVE isolate of F. hepatica behaves as resistant to ABZ and 19 
susceptible to TCBZ. 20 
 21 
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Introduction  1 
The trematode Fasciola hepatica is a cosmopolitan parasite which causes considerable 2 
loss in sheep and cattle production systems all over the world (Boray, 1994). As a result 3 
of climate change, there has been a dramatic resurgence of sheep and cattle fascioliasis in 4 
different regions of the world (Mitchell, 2002). Chemotherapy is the available main tool 5 
to control liver flukes. However, the frequent use of effective fluckicidal compounds 6 
leads to the development of resistance. Although resistance in flukes has not yet reached 7 
the levels roported in nematodes (Wolstenholme et al., 2004), failures of rafoxanide and 8 
closantel have been reported (Fairweather and Boray, 1999).  Most of the reports 9 
involving drug resistance in F. hepatica are related to triclabendazole (TCBZ), the most 10 
used flukicidal drug in veterinary medicine (Coles and Stafford, 2001). Unlike other 11 
benzimidazole (BZD) compounds, the halogenated derivative TCBZ has been shown to 12 
have an excellent efficacy against the mature and immature stages of F. hepatica (Boray 13 
et al., 1983). However, TCBZ activity appears to be restricted to the liver fluke and the 14 
lung fluke, Paragonimus spp. (Weber, et al., 1988; Calvopina et al., 1998), since the drug 15 
is inactive against nematodes, cestodes and other trematode parasites (Dicrocoelium 16 
dendriticum, Paramphistomun spp. and Schistosoma mansoni). The intensive use of 17 
TCBZ in endemic areas of fascioliasis has resulted in the development of liver flukes 18 
resistant to this compound (Overend and Bowen, 1995; Mitchell, et al., 1998; Moll et al., 19 
2000; Thomas et al., 2000; Olaechea et al., 2011), which is considered a major problem 20 
for veterinary therapeutics.  21 
 22 
Albendazole (ABZ) is the only BZD methylcarbamate recommended to control 23 
fascioliasis in domestic animals, despite its activity is restricted to flukes older than 12 24 
weeks (McKellar and Scott, 1990). A previously reported work (Coles and Stafford, 25 
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2001) has shown that ABZ was active against a TCBZ-resistant isolate of F. hepatica. 1 
On the other hand, resistance to both, ABZ and TCBZ in F. hepatica, has been reported 2 
in Spain (Alvarez-Sanchez et al., 2006). Since no alternative methods for fluke control 3 
are available, it is critical to understand how resistance is developed in order to limit its 4 
impact on livestock production (Wolstenholme et al., 2004). However, there are 5 
relatively few clearly defined isolates of F. hepatica available for study, and when new 6 
isolates become available they should be subjected to careful scrutiny to establish their 7 
response to different anthelmintic drugs (Fairweather, 2011). In order to gain a deeper 8 
insight on the mechanism involved on drug resistance in F. hepatica, it is relevant to 9 
investigate this resistance mechanisms in well characterized fluke isolates. The current 10 
work was designed to characterize the status of susceptibility/resistance to ABZ and 11 
TCBZ for a field isolate of F. hepatica, recovered from an Argentinean farm, which was 12 
initially suspected to be susceptible to TCBZ, maintained and artificially produced under 13 
laboratory conditions.  14 
 15 
 16 
Material and Methods 17 
Chemicals 18 
Pure (≥99%) standards of ABZ, ABZ-sulphoxide (ABZSO), ABZ-sulphone 19 
(ABZSO2), and oxibendazole (OBZ) used as internal standard (IS), were use in the 20 
present experiment. The commercial formulation of ABZ (Baxen 3.8%
®
, suspension) 21 
was from Tecnofarm, Argentina. TCBZ formulation (Fasinex
®
 10%, suspension) was 22 
from Novartis, Argentina. All the solvents (acetonitrile and methanol) used during the 23 
extraction and drug analysis were HPLC grade and purchased from Baker Inc. 24 
(Phillipsburg, NJ, USA). Water was double distilled and deionized using a water 25 
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purification system (Simplicity®, Millipore, Brazil). Buffer salts (ClNH4) were 1 
purchased from Baker Inc. (Phillipsburg, NJ, USA). 2 
 3 
Experimental design       4 
Animals 5 
Sixteen (16) healthy male Corriedale sheep (48.6 ± 2.6 kg) aged 24-26 months were 6 
involved in this trial. Animals were housed during the experiment and for 15 days 7 
before the start of the study. Animals were fed on a commercial balanced concentrate 8 
diet. Water was provided ad libitum. Animal procedures and management protocols 9 
were carried out in accordance with the Animal Welfare Policy (Act 087/02) of the 10 
Faculty of Veterinary Medicine, Universidad Nacional del Centro de la Provincia de 11 
Buenos Aires (UNCPBA), Tandil, Argentina (http://www.vet.unicen.edu.ar) and 12 
internationally accepted animal welfare guidelines (AVMA, 2001).  13 
 14 
F. hepatica isolate 15 
The F. hepatica isolate characterized in the current work (named CEDIVE isolate) was 16 
recovered from the farm “San Julian”, located in the Department of Gualeguay,  Entre 17 
Ríos, Argentina (32º 52´ S; 59º 25´ O). The farm, with a size of 1200 hectareas, is 18 
dedicated to raising cattle (700 heads) and sheep (1000 heads). In this farm, 4 to 5 19 
anthelmintic treatments per year have been used by several years in sheep. The 20 
treatments were based in the use of BZD compounds (mainly ABZ and oxfendazole), 21 
ivermectin and closantel. All anthelmintic treatments used in sheep were directed against 22 
gastrointestinal nematodes (Haemonchus spp and Trichostrongylus spp.). Although the 23 
presence of liver flukes has been found in both cattle and sheep, no specific treatments 24 
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against F. hepatica has been implemented, were it not for sporadic drenches in outbreaks, 1 
which mainly involved triclabendazole or closantel. Eggs of the F. hepatica isolate were 2 
recovered from the bile ducts of two sacrificed sheep, and subsequently maintained in 3 
donor animals and snails under laboratory conditions at the “Centro de Diagnóstico e 4 
Investigaciones Veterinarias” (CEDIVE), Facultad de Ciencias Veterinarias, Universidad 5 
Nacional de La Plata, Chascomús, Argentina.  6 
 7 
Experimental trials  8 
The drug-susceptibility characterization of the CEDIVE isolate of F. hepatica 9 
involved two separate experiments. Experiment 1: Each animal was orally infected 10 
with two hundred (200) metacercariae of the F. hepatica CEDIVE isolate. Sixteen 11 
weeks after infection, animals were randomly distributed into two experimental 12 
groups (n= 4 each): Control Group, which represented the untreated control and the 13 
ABZ Group, where the animals were treated with ABZ (Baxen 3.8%
®
, Tecnofarm, 14 
Argentina) by the i.r. route at the dose of 7.5 mg/kg. The ABZ reference product 15 
(Valbazen, Pfizer) was discontinued in Argentina. Since there were not available data 16 
on the plasma exposure of ABZ/metabolites after the use of the Baxen 3.8% 17 
formulation and, in order to discard treatment failures derived from the use of a poor 18 
quality formulation, a plasma pharmacokinetic study was also performed. For the 19 
pharmacokinetic study blood samples were taken by jugular venipunctures into 20 
heparinized Vacutainers

 tubes (Becton Dickinson, USA) before administration (time 21 
0) and at 1, 3, 6, 9, 12, 15, 24, 28, 32, 48 and 54 h post-treatment. Plasma was 22 
separated by centrifugation at 3000 g for 15 min, placed into plastic tubes and frozen 23 
at -20 ºC until analysis by high performance liquid chromatography (HPLC). 24 
 25 
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Experiment 2: Each experimental animal was orally infected with two hundred (200) 1 
metacercariae of the F. hepatica CEDIVE isolate. Sixteen weeks after infection, 2 
animals were randomly distributed into two experimental groups (n= 4 each): Control 3 
Group, which represented the untreated control and TCBZ Group, in which animals 4 
were treated with TCBZ (Fasinex
®
, Novartis, Argentina) by the i.r. route at the dose 5 
of 10 mg/kg.  6 
 7 
Clinical efficacy study 8 
Fifteen (15) days after treatment all animals were stunned and exsanguinated 9 
immediately. Adult F. hepatica specimens were recovered from the  main bile ducts 10 
and the gall bladder of each sheep and counted according to the World Association for 11 
the Advancement of Veterinary Parasitology (W.A.A.V.P) guidelines (Wood et al., 12 
1995). The efficacy of each anthelmintic treatment was determined by the comparison 13 
of F. hepatica burdens in treated versus untreated animals. The following equation 14 
expresses the percent efficacy (% E) of a drug treatment against F. hepatica (F.h.) in a 15 
single treatment group (T) when compared with an untreated control (C). 16 
 17 
 18 
 19 
 20 
The geometric mean was used as it most accurately represents the distribution of 21 
parasite populations within each group (Wood et al., 1995). 22 
 23 
           Mean of F.h. in C - mean of F.h. in T 
% E =                                                               · 100 
                         Mean of F.h. in C 
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Analytical procedures 1 
Plasma sample extraction: ABZ and its metabolites were extracted from plasma and 2 
quantified by HPLC as previously described (Alvarez et al, 2008). The HPLC was a 3 
Shimadzu 10 A System (Kyoto, Japan), which include a gradient pump, a UV detector 4 
set at 292 nm, an autosampler and a controller (Shimadzu Class LC10, Kyoto, Japan). 5 
Analytes were identified by the retention times of pure reference standards. Retention 6 
times for ABZSO, ABZSO2, OBZ, and ABZ were 5.32, 7.24, 9.55, and 11.14 min, 7 
respectively. There was no interference of endogenous compounds in the 8 
chromatographic determinations. Calibration curves for each analyte were prepared 9 
by least squares linear regression analysis, which showed correlation coefficients 10 
between 0.996 and 0.999. The absolute recovery of drug analytes from plasma was 11 
calculated by comparison of the peak areas from spiked plasma samples with the peak 12 
areas resulting from direct injections of standards in mobile phase. Mean absolute 13 
recoveries and coefficient of variations (CV) within the concentration range between 14 
0.1 and 4 µg/ml (triplicate determinations) were 91.3% (CV: 6.51%) (ABZ), 89.2% 15 
(CV: 5.40%) (ABZSO) and 92.2% (CV: 6.72%) (ABZSSO2). Precision (intra- and 16 
inter-assay) was determined by analysing replicates of fortified plasma samples (n= 5) 17 
with each compound at three different concentrations (0.1, 0.5 and 1 µg/ml). CV 18 
ranged from 3.50 to 12.5%. The limit of detection (LOD) was estimated by 19 
integrating the baseline threshold at the retention time of each compound in five non-20 
spiked plasma samples. The LOD was defined as the mean 'noise'/internal standard 21 
peak area ratio plus 3 standard deviations (SD). The limit of quantification (LOQ) was 22 
defined as the lowest measured concentration with a CV <20% and accuracy of ±20% 23 
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and an absolute recovery ≥70%. The LOQ defined for the three molecules assayed 1 
was 0.1 µg/ml. Values below LOQ were not included in the pharmacokinetic analysis.  2 
 3 
Pharmacokinetic analysis of the data 4 
Noncompartmental pharmacokinetic calculations for the concentration versus 5 
time curves for ABZ metabolites in plasma for each individual animal after the 6 
different treatments were conducted using the PK Solution 2.0 software (Summit 7 
Research Services, CO, USA).  The observed peak concentration (Cmax) and time to 8 
peak concentration (Tmax) were read from the plotted concentration-time curve of each 9 
analyte. The elimination (T½el) half life was calculated as ln2/β, where ß represent 10 
the terminal slope (h
-1
). The area under the concentration time-curve (AUC) was 11 
calculated by the trapezoidal rule (Gibaldi and Perrier, 1982) and further extrapolated 12 
to infinity by dividing the last experimental concentration by the terminal slope (β). 13 
Statistical moment theory was applied to calculate the mean residence time (MRT) for 14 
metabolites in plasma, as follows: MRT= AUMC/AUC, where AUC is as defined 15 
previously and AUMC is the area under the curve of the product of time and the 16 
plasma drug concentration versus time from zero to infinity (Gibaldi and Perrier, 17 
1982). 18 
 19 
Statistical analysis of the data 20 
Pharmacokinetic parameters are presented as mean ± SD. Fluke counts in each 21 
experimental group within each experiment were compared by non parametric test 22 
(Mann-Whitney Test). A value of P<0.05 was considered statistically significant. 23 
 24 
25 
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Results  1 
Table 1 shows the parasite counts and the clinical efficacy (%) for ABZ and TCBZ 2 
against the CEDIVE isolate of F. hepatica in sheep. Efficacy values from 29% (ABZ) 3 
and 100 % (TCBZ) were observed. No statistical differences (P>0.05) were observed 4 
in fluke counts between ABZ treated and untreated control groups. Furthermore, a 5 
significantly (P<0.05) decrease in fluke counts were observed in TCBZ treated 6 
animals, in comparison to the counting in untreated animals.  7 
 8 
ABZSO and ABZSO2 were the only analytes recovered in plasma after the i.r. 9 
administration of ABZ. The active ABZSO was the main metabolite measured in 10 
plasma up to 48 h post-treatment. The comparative mean (± SD) plasma concentration 11 
profiles of ABZSO and ABZSO2 obtained after the i.r. administration of ABZ are 12 
shown in Figure 1. The plasma disposition kinetics data for ABZSO and ABZSO2 13 
after i.r. administration of ABZ are summarized in Table 2. The plasma exposure 14 
(expressed as AUC and Cmax) of ABZ metabolites observed in the ABZ treated 15 
animals (Experiment 1), was in agreement with previous data obtained in our 16 
laboratory (Table 3). The ABZSO AUC value obtained after ABZ administration in 17 
the current experiment (41.1 ± 13.9 µg.h/ml) was similar to that obtained by Alvarez 18 
et al, 1997 (41.8 ± 2.28 µg.h/ml), Alvarez et al, 1999 (46.0 ± 5.72 µg.h/ml) and 19 
Moreno et al., 2004 (31.2 ± 5.43 µg.h/ml), in which the reference formulation of ABZ 20 
(Valbazen®, ABZ 10%, Pfizer Animals Health, Argentina) was used. A similar 21 
pattern was observed for the Cmax parameter.  22 
23 
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Discussion  1 
The results reported here clearly demonstrate that the CEDIVE isolate of F. hepatica 2 
behaves as resistant to ABZ and susceptible to TCBZ. Interestingly, in the farm 3 
where the CEDIVE isolate of F. hepatica was obtained, anthelmintic treatments are 4 
only addressed to control GI nematodes. However, it seems clear that the high 5 
selection pressure exerted by this practice has contributed to the development of 6 
resistance not only in nematodes but even so in liver flukes.  7 
 8 
The manufacturing process, the quality of the active ingredient/excipients and their 9 
long standing stability, among other factors involved in the production of generic 10 
formulations (suspensions), may substantially affect the drug dissolution process and 11 
its consequent GI absorption, which in turns could affect drug effectiveness. In fact, 12 
factors related to the quality of the active ingredient have been associated with 13 
therapeutic failure of generic rafoxanide formulations against Haemonchus contortus 14 
in sheep (Van Wyk et al., 1997). Furthermore, it has been recently demonstrated that 15 
different generic ABZ formulations commercialized in Uruguay could not be assessed 16 
as bioequivalent to the pioneer preparation (Suarez et al., 2011). In the current work, 17 
the plasma drug exposure of ABZ metabolites observed after its administration as a 18 
“generic” formulation (Baxen 3.8%
®
), resulted similar to that reported after the 19 
administration of the reference formulation (Valbazen
®
) in sheep at the same dose. 20 
The AUC and Cmax values were in the range of those reported by Alvarez et al, 21 
1997; 1999 and Moreno et al., 2004. These results discard the fact that the observed 22 
ABZ failure to control liver flues may have given by a poor quality formulation 23 
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resulting in reduced drug systemic exposure. This was not the case in the work 1 
reported here.  2 
 3 
The intrinsic anthelmintic action of BZD compounds relies on a progressive 4 
disruption of basic cell functions as a result of their binding to parasite β-tubulin and 5 
depolimerization of microtubules (Lacey, 1988). BZD resistance in nematodes has 6 
been linked to the loss of high-affinity binding to tubulin (Lubega and Prichard, 7 
1991a) and an alteration of the β-tubulin isoform pattern (Lubega and Prichard, 8 
1991b), correlated with a conserved mutation at amino acid 200 (phenylalanine to 9 
tyrosine: F200Y) in tubulin isotype 1 (Kwa et al., 1994). While experimental data 10 
supports a microtubule-based action for TCBZ (reviewed by Fairweather, 2005), it 11 
has been shown that the TCBZ-resistant phenotype is not associated with residue 12 
changes (specifically, the F200Y mutation) in the primary amino acid sequence of β-13 
tubulin (Robinson et al., 2002). In fact, the accumulated in vitro data demonstrate that 14 
at least two mechanisms appear to be implicated in TCBZ resistance in F. hepatica: 15 
increased drug efflux and enhanced oxidative metabolism (Robinson et al., 2004; 16 
Alvarez et al., 2005a; Mottier et al., 2006; Devine et al., 2009; Devine et al., 2010). 17 
A previous study has shown that ABZ is active against a TCBZ-resistant isolate of F. 18 
hepatica (Coles and Stafford, 2001). The greater trans-tegumental diffusion capability 19 
of ABZ compared to TCBZ under ex vivo conditions, may account for its efficacy 20 
pattern against TCBZ-resistant flukes (Alvarez et al., 2005b). However, the CEDIVE 21 
isolate results resistant to ABZ and susceptible to TCBZ. These results may indicate 22 
that a different mechanism could be implicated in the development of resistance to each 23 
compound, it is likely that TCBZ may target a molecule other than ß-tubulin, which 24 
13 
 
would explain why ABZ continues to act against TCBZ-resistant flukes. To complicate 1 
the picture, resistance to ABZ and TCBZ in F. hepatica has been reported in Spain 2 
(Alvarez-Sanchez et al., 2006). It is, therefore clear, that the mechanism involved on 3 
ABZ resistance in F. hepatica need to be elucidated. 4 
 5 
Conclusions  6 
The data reported here indicate that the CEDIVE isolate of F. hepatica is resistant to 7 
ABZ and susceptible to TCBZ. The fact that the CEDIVE isolate is maintained under 8 
laboratory conditions, may help to further understand the mechanism(s) of ABZ 9 
resistance in F. hepatica.  10 
  11 
Acknowledgements  12 
This research was supported by the Agencia Nacional de Promoción Científica y 13 
Tecnológica and CONICET, both from Argentina. 14 
 15 
Figure captions 16 
Figure 1: Comparative mean (±SD) plasma concentration profiles (n= 4) for 17 
albendazole sulphoxide (ABZSO), after the administration of albendazole 18 
(Baxen3.8%®, 7.5 mg/kg) to sheep infected with Fasciola hepatica. 19 
20 
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Figures 1 
Figure 1. ABZSO and ABZSO2 plasma concentrations inFasciola hepatica-2 
infected sheep (mean and standard deviations). 3 
 4 
 5 
Table 1. Individual and mean fluke counts and clinical efficacy (%) against the 6 
CEDIVE Fasciola hepatica isolate, obtained after the administration of albendazole 7 
(ABZ, 7.5 mg/kg, i.r.) or triclabendazole (TCBZ, 10 mg/kg, i.r.) in sheep.    8 
 9 
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# 1 112 60 27 0 
# 2 67 25 23 0 
# 3 43 69 15 0 
# 4 67 55 29 0 
Arithmetic mean 72.3 52.3 23.5 0 
Efficacy* - 29 %  100% 
* The efficacy was calculated using geometric means.   1 
 2 
 3 
Table 2. Plasma pharmacokinetic parameters (mean ± SD) for albendazole 4 
sulphoxide (ABZSO) and albendazole sulphone (ABZSO2) obtained after the 5 
intraruminal (i.r.) administration of albendazole (ABZ, 7.5 mg/kg) to Fasciola 6 
hepatica infected sheep.  7 
 8 
 
PHARMACOKINETIC 
PARAMETERS 
 
ABZSO 
 
ABZSO2 
Cmax (µg/mL) 1.40 ± 0.47 0.50 ± 0.10 
Tmax (h) 16.5 ± 5.20 30.0 ± 2.30 
AUC0-t (µg.h/mL) 41.1 ± 13.9 15.9 ± 5.30 
T½el (h) 8.70 ± 0.80 7.30 ± 0.60 
MRT (h) 23.1 ± 2.14 29.6 ± 1.80 
9 
19 
 
Table 3. Comparative peak plasma concentration (Cmax)and area under the 1 
concentration vs time curve (AUC) for albendazole sulphoxide (ABZSO), obtained 2 
after the i.r. administration of albendazole (7.5 mg/kg) as a 3.8% formulation (Baxen 3 
3.8%
®
, Tecnofarm, Argentina, current work) or as a 10% formulation (Valbazen, 4 
Pfizer Animal Health, Argentina, reference formulation)(works from Alvarez et al., 5 
1997; 1999 and Moreno et al., 2004) to sheep.    6 
 7 
ABZSO 
PK Parameter 
Current 
work 
Alvarez et al., 
1997 
Alvarez et al., 
1999 
Moreno et al., 
2004 
 
Cmax (µg/ml) 
 
1.40 ± 0.47 
 
1.76 ± 0.16 
 
1.92 ± 0.26 
 
1.23 ± 0.24 
 
AUC (µg.h/ml) 
 
41.1 ± 13.9 
 
41.8 ± 2.28 
 
46.0 ± 5.72 
 
31.2 ± 5.43 
 8 
 9 
